WRN inhibitor 11, identified by its CAS number 3058317-61-3, is a small molecule that acts as an inhibitor of the Werner syndrome protein (WRN), which is a member of the RecQ helicase family. This protein plays a crucial role in DNA repair, replication, and maintenance of genomic stability. The inhibition of WRN has potential therapeutic implications, particularly in cancer treatment, as cancer cells often exhibit elevated WRN activity to cope with the increased DNA damage associated with rapid cell division. WRN inhibitor 11 is characterized by its specific binding affinity to the WRN helicase domain, disrupting its function and thereby enhancing the sensitivity of cancer cells to DNA-damaging agents. The compound's efficacy and selectivity are subjects of ongoing research, with studies focusing on its pharmacokinetics, toxicity profile, and potential synergistic effects when used in combination with other anticancer therapies. Overall, WRN inhibitor 11 represents a promising avenue for targeted cancer therapy, particularly in tumors with defective DNA repair mechanisms.

WRN inhibitor 11

3058317-61-3: WRN inhibitor 11, identified by its CAS number 3058317-61-3, is a small molecule that acts as an inhibitor of the Werner syndrome protein (WRN), which is a member of the RecQ helicase family. This protein plays a crucial role in DNA repair, replication, and maintenance of genomic stability. The inhibition of WRN has potential therapeutic implications, particularly in cancer treatment, as cancer cells often exhibit elevated WRN activity to cope with the increased DNA damage associated with rapid cell division. WRN inhibitor 11 is characterized by its specific binding affinity to the WRN helicase domain, disrupting its function and thereby enhancing the sensitivity of cancer cells to DNA-damaging agents. The compound's efficacy and selectivity are subjects of ongoing research, with studies focusing on its pharmacokinetics, toxicity profile, and potential synergistic effects when used in combination with other anticancer therapies. Overall, WRN inhibitor 11 represents a promising avenue for targeted cancer therapy, particularly in tumors with defective DNA repair mechanisms.

<p>WRN inhibitor 11 (Example 17) is an orally effective inhibitor of WRN helicase, with an IC50 of 63 nM.</p>

CAS 3058317-61-3

WRN inhibitor 11

WRN inhibitor 11

Ref: TM-T201262